Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Cancer genes differ in different parts of a tumour

Share :

IMPAKT 2012
Published: 17 May 2012
Views: 4350
Rating:
Save
Prof Charles Swanton - CRUK London Research Institute and UCL, UK

Prof Swanton talks to ecancer at the IMProving care And Knowledge through Translational research (IMPAKT) meeting in Brussels, May 2012, about variations within the tumour itself and the implications for new types of personalized medicine.

 

Read more here

 

Filming Supported by Amgen

Related Videos

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer

Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA
Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer ( Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA )
14 Sep 2024

Biomarkers, predictive and prognostic factors of resistance to immunotherapy

Dr Ignacio Gil-Bazo - Fundación Instituto Valenciano de Oncología (FIVO)/Clínica Universidad de Navarra, Spain
Biomarkers, predictive and prognostic factors of resistance to immunotherapy ( Dr Ignacio Gil-Bazo - Fundación Instituto Valenciano de Oncología (FIVO)/Clínica Universidad de Navarra, Spain )
12 Jul 2024

Hormonal receptor positive breast cancer adjuvant and metastatic indications

Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA
Hormonal receptor positive breast cancer adjuvant and metastatic indications ( Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA )
12 Jul 2024

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom
ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )
26 Jun 2024

Addition of atezolizumab to chemotherapy after surgery does not improve survival for triple negative breast cancer

Dr Heather McArthur - UT Southwestern Medical Center, Dallas, USA
Addition of atezolizumab to chemotherapy after surgery does not improve survival for triple negative breast cancer ( Dr Heather McArthur - UT Southwestern Medical Center, Dallas, USA )
26 Apr 2024

EBCC 2024: Addressing inequalities across Europe in access to innovation for patients with metastatic breast cancer

Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) and Dr Michail Ignatiadis (Institut Jules Bordet, Brussels, Belgium)
EBCC 2024: Addressing inequalities across Europe in access to innovation for patients with metastatic breast cancer ( Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) and Dr Michail Ignatiadis (Institut Jules Bordet, Brussels, Belgium) )
25 Apr 2024

Comment: EBCC 2024 highlights

Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) andDr Michail Ignatiadis (Institut Jules Bordet, Brussels, Belgium)
Comment: EBCC 2024 highlights ( Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) andDr Michail Ignatiadis (Institut Jules Bordet, Brussels, Belgium) )
25 Apr 2024

Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Housten, USA
Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Housten, USA )
24 Apr 2024

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )
25 Mar 2024

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation